At a glance
ClinicalIndex Comparison RecordN/ACompleted· 38 enrolled
Drug / intervention
Macugendrug
Likely dose
Macugen 0.3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration (AMD) In Real Life (Macureli Study).
In Brief
An observational study evaluating Macugen for Neovascular Age-related Macular Degeneration. Completed, enrolled 38 participants across 4 sites.
Detailed Summary
To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity. Treatment duration, frequency of administration and combination with other treatments will also be evaluated.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartNov 2007
Primary CompletionOct 2009
TodayJul 2026
First PostedOct 25, 2007
Enrollment StartNov 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.7 years ago
Interventions
Macugendrug
Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)